They focused on the metabolic preference of AML progenitor cells and diverse immune cells and proposed potential targets for AML metabolic therapy, including ENO1, GSTP1, MT-ND4L and UQCR11. This evidence concerns the gene UQCR11 and acute myeloid leukemia.